Fig. 3. Treatment with azacitidine and decitabine results in differential methylation and transcriptional changes.
A Manhattan plots showing differential methylation profiles across genome-wide CpG sites of six KMT2A-rearranged infant acute lymphoblastic leukemia cell lines treated at low dose (1.5 µM) with the hypomethylating agents azacitidine and decitabine in comparison to untreated controls. Differentially methylated CpG sites were mapped to their corresponding loci across the genome (x axis) and plotted against their significance levels (-log10 transformed p-values) (y axis), from comparisons between treated and untreated cell lines. The red line indicates genome-wide significance threshold of 5 × 10−8, and the blue line indicates suggestive significance, valued at 1 × 10−5. B Volcano plots highlighting the top differentially expressed genes from the merged transcriptome of all six cell lines following treatment with azacitidine and decitabine. Horizontal and vertical dashed lines indicate fold change and significance thresholds.